StockData
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Neuphoria Therapeutics Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026
$3.31+0.01 (+0.30%)

Close on Oct 19, 2026

Market cap
$17.90M
P/E (TTM)
–
Dividend yield
–

Neuphoria Therapeutics Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Neuphoria Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.